Page last updated: 2024-10-18
glycine and Chronic Bronchitis
glycine has been researched along with Chronic Bronchitis in 1 studies
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| " The self-propagating acetyl-proline-glycine-proline (AcPGP) pathway is a novel means of neutrophilic inflammation that is pathologic in the development of COPD." | 9.20 | A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease. ( Bailey, WC; Bhatt, SP; Blalock, JE; Dransfield, MT; Gaggar, A; Gautney, J; Handley, G; Jackson, PL; King, RW; Viera, L; Wells, JM; Xu, X, 2015) |
| " The self-propagating acetyl-proline-glycine-proline (AcPGP) pathway is a novel means of neutrophilic inflammation that is pathologic in the development of COPD." | 5.20 | A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease. ( Bailey, WC; Bhatt, SP; Blalock, JE; Dransfield, MT; Gaggar, A; Gautney, J; Handley, G; Jackson, PL; King, RW; Viera, L; Wells, JM; Xu, X, 2015) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Wells, JM | 1 |
| Jackson, PL | 1 |
| Viera, L | 1 |
| Bhatt, SP | 1 |
| Gautney, J | 1 |
| Handley, G | 1 |
| King, RW | 1 |
| Xu, X | 1 |
| Gaggar, A | 1 |
| Bailey, WC | 1 |
| Dransfield, MT | 1 |
| Blalock, JE | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| A Placebo-controlled Trial of Roflumilast (Daliresp) on Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD)[NCT01572948] | | 27 participants (Actual) | Interventional | 2012-06-30 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Induced Sputum Neutrophil Count
(NCT01572948)
Timeframe: 1 month
| Intervention | percentage of sputum neutrophils (Mean) |
|---|
| Placebo | 83 |
| Daliresp | 80 |
Induced Sputum Neutrophil Count
(NCT01572948)
Timeframe: 3 months after baseline
| Intervention | percentage of sputum neutrophils (Mean) |
|---|
| Placebo | 86 |
| Roflumilast | 58 |
Induced Sputum Neutrophil Count
(NCT01572948)
Timeframe: baseline
| Intervention | percentage of sputum neutrophils (Mean) |
|---|
| Placebo | 89 |
| Roflumilast | 83 |
Induced Sputum Proline-glycine-proline (PGP) Levels at Baseline
(NCT01572948)
Timeframe: baseline
| Intervention | ng/ml (Mean) |
|---|
| Placebo | 0.74 |
| Roflumilast | 0.64 |
Mean Induced Sputum Proline-glycine-proline (PGP) Levels at 1 Month After Randomization.
(NCT01572948)
Timeframe: 1 month after baseline
| Intervention | ng/ml (Mean) |
|---|
| Roflumilast | .33 |
| Placebo | .66 |
Mean Induced Sputum Proline-glycine-proline (PGP) Levels at 3 Months After Randomization
(NCT01572948)
Timeframe: 3 months after baseline
| Intervention | ng/ml (Mean) |
|---|
| Placebo | 0.70 |
| Roflumilast | 0.30 |
Trials
1 trial available for glycine and Chronic Bronchitis